Maintenance therapy with pazopanib improved progression-free survival by 5.6 months in advanced ovarian cancer patients, according to results of a new study
A large meta-analysis found that women who were users of hormone therapy, even those with less than 5 years of use, had an increased risk of ovarian cancer.
Despite achieving complete surgical resection, advanced epithelial ovarian cancer or primary peritoneal cancer patients with a high disease burden had worse survival outcomes than those with lower disease burden.
Women with bilateral malignant ovarian germ cells tumors may still have a good prognosis and may be able to maintain fertility with conservative treatment.
Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.
By clicking Accept, you agree to become a member of the UBM Medica Community.
![Subscribe to Ovarian Cancer on [sitename]](http://www.cancernetwork.com/misc/feed.png){kind=small}
